These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33299330)
1. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report. Chen Y; Zhang H; Shi J; Wang T Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330 [TBL] [Abstract][Full Text] [Related]
2. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report. Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549 [TBL] [Abstract][Full Text] [Related]
3. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323 [TBL] [Abstract][Full Text] [Related]
4. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient. Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J Front Oncol; 2023; 13():1280208. PubMed ID: 38090483 [TBL] [Abstract][Full Text] [Related]
5. Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report. Wang C; Lei K; Jia Y; Jiang Z; Wang S Exp Ther Med; 2023 Jul; 26(1):324. PubMed ID: 37346410 [TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review. Kong F; Wang W; Gong L; Wu W; Liu Y J Clin Pharm Ther; 2020 Dec; 45(6):1489-1496. PubMed ID: 32776600 [TBL] [Abstract][Full Text] [Related]
7. Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma. Ma R; Wang JL; Wang YY Exp Hematol Oncol; 2022 Oct; 11(1):78. PubMed ID: 36289520 [TBL] [Abstract][Full Text] [Related]
8. Camrelizumab: an investigational agent for hepatocellular carcinoma. Xu B; Sun HC Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475 [TBL] [Abstract][Full Text] [Related]
9. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report. Hua Y; Huang X; Li C; Gao N Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature. Li L; Lou A; Yu J Ann Palliat Med; 2021 Jul; 10(7):8460-8466. PubMed ID: 34044548 [TBL] [Abstract][Full Text] [Related]
11. Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. Senoo S; Ninomiya T; Makimoto G; Nishii K; Kano H; Watanabe H; Hata Y; Kubo T; Tanaka T; Hotta K; Maeda Y; Kiura K Intern Med; 2019 Apr; 58(7):985-989. PubMed ID: 30568113 [TBL] [Abstract][Full Text] [Related]
12. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab. Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y Front Immunol; 2023; 14():1221418. PubMed ID: 37575222 [TBL] [Abstract][Full Text] [Related]
13. Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report. Ni K; Wang Z; Yu S; Zheng J; Li G Transl Androl Urol; 2021 Apr; 10(4):1821-1826. PubMed ID: 33968671 [TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment. Wang D; Zhang S; Ding P; Zhao Y; Zhang X; Zhao Q Iran J Immunol; 2020 Jun; 17(2):167-171. PubMed ID: 32602470 [TBL] [Abstract][Full Text] [Related]
15. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China. Qu W; Wang F; Qin S; Sun Y; Huang C Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164 [TBL] [Abstract][Full Text] [Related]
16. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052 [TBL] [Abstract][Full Text] [Related]
17. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J; Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. Wan Y; Wang Z; Yang N; Liu F Front Oncol; 2022; 12():911961. PubMed ID: 35865468 [TBL] [Abstract][Full Text] [Related]
19. Successful response to camrelizumab in metastatic bladder cancer: A case report. Xie C; Yuan X; Chen SH; Liu ZY; Lu DL; Xu F; Chen ZQ; Zhong XM World J Clin Cases; 2022 Jan; 10(1):254-259. PubMed ID: 35071525 [TBL] [Abstract][Full Text] [Related]
20. Immune-Related Colitis Induced by Camrelizumab: A Case Report. Cheng S; Yang Y; Yu J; Chen W; Li X J Inflamm Res; 2023; 16():1727-1731. PubMed ID: 37096128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]